Protein Advances, Inc.

Seattle, WA 98102

SBIR Award Summary

Total Number of Awards 20
Total Value of Awards $9.72MM
Active Awards 2 valued at $886K
First Award Date 09/01/07
Most Recent Award Date 08/01/17

2 Active Awards Valued at $886K

Award Title Awarding Agency Phase Award amount Start Date End Date
Development of a Prophylactic Onchocerciasis Vaccine HHS 1 $442K 08/31/16 08/30/18
Combining Parasite and Vector Components for Development of a Leishmania Vaccine HHS 1 $444K 08/31/16 08/30/18

Key Personnel

Last Name Name Awards Contact
Carter Darrick Albert Carter 16
Siddiqui Afzal A Siddiqui 4
COLER RHEA N COLER 3
STINCHCOMB DAN THOMAS STINCHCOMB 1
VAN HOEVEN NEAL SCOTT VAN HOEVEN 1

20 Awards Won

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-16-303
Budget: 08/01/17 - 01/31/18

Project Summary Chagas disease is a severe inflammatory syndrome caused by infection with a protozoan parasite, Trypanosoma cruzi. Although transmission occurs mostly through an intermediate insect host, the infection is silent and chronic carriers pose a significant risk through the transfer of infected products made from donated blood of these...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 03/15/17 - 02/28/18

PROJECT SUMMARY/ABSTRACT: Chikungunya virus (CHIKV) is an emerging disease of global public health importance. Originally identified in 1952, sporadic CHIKV outbreaks occurred in Africa and Asia for several decades. Beginning with an outbreak on the island of La Reunion in 2004 the virus has continued to spread to new regions around the globe. C...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 01/01/17 - 12/31/17

? DESCRIPTION (provided by applicant): Schistosomiasis is a major neglected tropical disease of public health concern to a billion people with 200 million currently infected and 779 million at risk to acquire the infection, the majority of these in Africa. The disease has a high impact on affected people's lives with disability adjusted life...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 09/20/16 - 03/31/17

Project Summary Tumors survive cancer therapy in part by blocking the entrance and permeation of drugs into the cancer. We have developed a conjugatable therapeutic, ?JOC-x?, that selectively opens up tumor tight junctions, which dramatically enhances penetration. This results in markedly increased concentrations of cancer drugs in the tumor. JO...

Phase 1 SBIR Active

Agency: Department of Health & Human Services
Topic:
Budget: 08/31/16 - 08/30/18

To use sandfly and parasite antigens to develop a visceral leishmaniasis vaccine.

Phase 1 SBIR Active

Agency: Department of Health & Human Services
Topic:
Budget: 08/31/16 - 08/30/18

To develop an onchocerciasis vaccine to be used for disease control and elimination.

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 03/01/16 - 02/28/17

? DESCRIPTION (provided by applicant): A problem with hematopoietic stem cell (HSC) transplantation is the risk of primary or secondary graft failure. As an example, in patients with hematologic malignancies who underwent their first myeloablative allogeneic hematopoietic cell transplantation, primary graft failure is 5.5%. One year overall s...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 01/01/16 - 12/31/16

? DESCRIPTION (provided by applicant): Schistosomiasis is a major neglected tropical disease of public health concern to a billion people with 200 million currently infected and 779 million at risk to acquire the infection, the majority of these in Africa. The disease has a high impact on affected people's lives with disability adjusted life...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/15/15 - 09/14/17

Development of improved drug regimens to shorten treatment for multi-drug resistant (MDR) and drug-susceptible (DS) TB and improve tolerance and safety is an extremely high research priority. Clofazimine (CFZ) is a drug approved decades ago for treatment of leprosy. Animal studies of the drug for TB treatment indicate that it may significantly r...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 07/01/15 - 06/30/16

DESCRIPTION (provided by applicant): Tuberculosis (TB), a disease caused by Mycobacterium tuberculosis (Mtb), is an ongoing threat to public health. Globally, approximately two billion people are infected with TB, with nine million newly diagnosed cases of active TB each year causing 1.5 million deaths. Furthermore, mismanagement or inappropriat...

Load More